Blood cancer patients may need higher antibiotic doses to beat superbugs

NCT ID NCT07703644

Not yet recruiting Knowledge-focused Sponsor: Sizhou Feng Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study looks at whether the standard dose of the antibiotic ceftazidime-avibactam reaches high enough levels in the blood of people with blood cancers or those who have had a stem cell transplant. These patients are at high risk for severe infections from drug-resistant bacteria. Researchers will measure drug levels and track whether the infection clears and if the bacteria become resistant during treatment. The goal is to find out if the usual dose is adequate for this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ceftazidime-avibactam (CAZ-AVI), an antibiotic combination given intravenously
What this could lead to: If successful, this study could help doctors optimize antibiotic dosing for vulnerable blood cancer patients, potentially improving infection outcomes and slowing the rise of drug-resistant bacteria.
What could go wrong: This is a small, observational study that does not test a new treatment or change how the drug is given. It only measures drug levels and outcomes, so it cannot prove that adjusting doses would improve survival or reduce resistance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG RESISTANCE, BACTERIAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gram-negative bacterial infections hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Klebsiella pneumonia Pseudomonas aeruginosa infectious disease Pseudomonas infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG RESISTANCE, BACTERIAL GRAM-NEGATIVE BACTERIAL INFECTIONS HEMATOLOGIC NEOPLASMS KLEBSIELLA PNEUMONIAE INFECTIONS PSEUDOMONAS AERUGINOSA INFECTION

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, 300020, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.